- Home
- LPTH vs TCRX Comparison
LPTH vs TCRX Comparison
Compare LPTH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- TCRX
- Stock Information
- Founded
- LPTH 1985
- TCRX 2018
- Country
- LPTH United States
- TCRX United States
- Employees
- LPTH N/A
- TCRX N/A
- Industry
- LPTH Semiconductors
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LPTH Technology
- TCRX Health Care
- Exchange
- LPTH Nasdaq
- TCRX Nasdaq
- Market Cap
- LPTH 81.1M
- TCRX 90.5M
- IPO Year
- LPTH 1996
- TCRX 2021
- Fundamental
- Price
- LPTH $2.41
- TCRX $1.38
- Analyst Decision
- LPTH Strong Buy
- TCRX Strong Buy
- Analyst Count
- LPTH 3
- TCRX 7
- Target Price
- LPTH $4.67
- TCRX $9.86
- AVG Volume (30 Days)
- LPTH 101.0K
- TCRX 396.8K
- Earning Date
- LPTH 05-15-2025
- TCRX 05-06-2025
- Dividend Yield
- LPTH N/A
- TCRX N/A
- EPS Growth
- LPTH N/A
- TCRX N/A
- EPS
- LPTH N/A
- TCRX N/A
- Revenue
- LPTH $32,158,517.00
- TCRX $4,421,000.00
- Revenue This Year
- LPTH $16.90
- TCRX $47.30
- Revenue Next Year
- LPTH $52.77
- TCRX $74.30
- P/E Ratio
- LPTH N/A
- TCRX N/A
- Revenue Growth
- LPTH N/A
- TCRX N/A
- 52 Week Low
- LPTH $1.04
- TCRX $1.02
- 52 Week High
- LPTH $4.42
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- LPTH 59.62
- TCRX 42.86
- Support Level
- LPTH $2.27
- TCRX $1.32
- Resistance Level
- LPTH $2.55
- TCRX $1.65
- Average True Range (ATR)
- LPTH 0.15
- TCRX 0.13
- MACD
- LPTH 0.03
- TCRX -0.01
- Stochastic Oscillator
- LPTH 78.46
- TCRX 14.63
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.